Plain-English translation of NCT07714512 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a monoclonal antibody (a type of engineered protein), to see if it can help patients with refractory severe aplastic anemia—a serious condition where the bone marrow fails to produce enough blood cells and standard treatments haven't worked. The study has two parts: first, researchers will test different doses of the medication to find the safest and most effective dose; then, they will test whether this treatment can actually help patients recover their blood cell counts.
Severe aplastic anemia is a life-threatening condition, and many patients don't respond well to current standard treatments like immunosuppressive therapy or blood cell growth stimulators. This trial exists to see if this new medication might offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the medication, likely through regular clinic visits for dosing and monitoring. The study is divided into two phases: in phase 1, the research team will gradually increase doses in small groups of patients to find the safest dose; in phase 2, a larger group will receive the chosen dose to see if it actually helps patients recover blood cell counts. You will have blood tests and clinical visits to monitor your response and watch for side effects. The exact duration and visit schedule will be explained to you during enrollment.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
China